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Modeling Pharmaceutical Inhibition of Glucose-Stimulated Renin-Angiotensin System in Kidneys 
Diabetic hyperglycemia is known to induce kidney damage by causing injury to renal cells known as 
podocytes. The cells are critical in maintaining the filtration function of kidney. These cells express 
hormones of the renin-angiotensin system (RAS) intracellularly in a manner that is altered in 
hyperglycemic conditions. The key hormone that is overexpressed and can lead to kidney damage is 
angiotensin II (ANG II). The enzyme responsible for production of ANG II from precursors is angiotensin 
converting enzyme (ACE). A pharmacokinetic/pharmacodynamic model is developed for localized 
intracellular RAS to predict the effect of an ACE inhibitor pharmaceutical to suppress elevated ANG II 
levels. The results of this model are compared to a previously developed model for the RAS expressed 
systemically.  
 
